Actionable news
All posts from Actionable news
Actionable news in CYTK: Cytokinetics, Incorporated,

Analysts Offer Commentary On Two Biotech Stocks: Merrimack Pharmaceuticals Inc (MACK), Cytokinetics, Inc. (CYTK)


Analysts weigh in on the biopharmaceutical company Merrimack Pharmaceuticals Inc (NASDAQ:MACK) and biotechnology company Cytokinetics, Inc. (NASDAQ:CYTK), with positive ratings and views.

Merrimack Pharmaceuticals Inc

In a research note released today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Merrimack Pharmaceuticals, with a price target of $16, following the news that the FDA has approved the company’s Onivyde (formerly known as MM-398) in combination with fluorouracil and leucovorin (5-FU/LV) for the treatment of gemcitabineexperienced patients with advanced pancreatic cancer.

Aschoff observed, “Onivyde is the first FDA approved treatment for patients in the post-gemcitabine pancreatic cancer setting, and was approved with serious adverse event labeling consistent with irinotecan (boxed warning for severe neutropenia and diarrhea). Merrimack expects to have Onivyde available in the US next Monday, with its distribution network in place. Its unique approval niche in post-gemcitabine pancreatic cancer should facilitate uptake.”

“We do not view the boxed warning as a great concern, given the severity of...